1. Scrip
  2. >>Business

End In Sight: Humira Stacks Up 20 Years Of US Market Exclusivity

 
• By Jessica Merrill

AbbVie, for the second time, has resolved a Humira patent dispute that protects the drug's US commercial exclusivity until 2023. The latest deal with Samsung Biopesis follows a similar agreement with Amgen, giving Amgen a five-month head start with its biosimilar. 

Businesswoman Hands On Crystal Ball On Black Background. Fortune Teller Predicting Future

AbbVie Inc. appears well positioned to maintain the US commercial exclusivity of its blockbuster autoimmune disease drug Humira (adalimumab) for 20 years from its launch, many of those years as the world's top-selling drug. The company announced the resolution of a second patent dispute April 5, this time with Samsung Bioepis Co. Ltd., which will protect Humira's market exclusivity in the US until June 30, 2023.

In Europe, Samsung's biosimilar version of Humira can launch earlier, on Oct. 16, 2018. The biosimilar, Imraldi, was approved by...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Business

Lupin’s Cimzia Biosimilar Candidate Reflects Strategy To Separate Wheat From Chaff

 
• By Vibha Ravi

Lupin's choice of a Cimzia biosimilar candidate and partnering with Zentiva reflect a strategy to sort the wheat from the chaff. Of 118 biologics to lose patent protection between 2025 and 2034 as per IQVIA, it’s going for a biosimilar with a single competitor though there could be other spoilers

Finance Watch: Two New Venture Capital Funds Provide $600m For Biopharma

 
• By Mandy Jackson

Private Company Edition: Catalio raised more than $400m for its fourth health care-focused VC fund, while AN Venture Partners raised $200m for Japan and beyond. In VC financings, among a dearth of mega rounds, Neuron23’s $96.5m series D is the largest round in recent weeks.

Merck & Co.’s Verona Acquisition Marks A Return To Respiratory

 
• By Jessica Merrill

With the $10bn acquisition of Verona, Merck gains the marketed COPD drug Ohtuvayre, reentering respiratory, where it was once a leader with Singulair.